|
Flu (influenza) Information |
| Afluria
flu (influenza) vaccine |
 |
|
| Manufacturer |
CSL Biotherapies |
| Microorganism |
influenza virus |
| Licensed |
09/28/2007 |
| Recommendations |
One intramuscular injection |
| Ingredients |
Beta-propiolactone, Neomycin, Polymyxin B, Sucrose, Thimerosal, Mercury, Sodium phosphate-monobasic, Chick embryo cells, Potassium chloride, Neomycin sulphate, Calcium chloride, Sodium deoxycholate, Sodium phosphate- dibasic anhydrous, Potassium phosphate- monobasic. |
Product Descriptions
|
Package Insert
|
| Agriflu
trivalent inactivated influenza virus vaccine |
|
|
|
| Manufacturer |
Novartis Vaccines and Diagnostics, Inc. |
| Microorganism |
influenza virus subtypes A and type B, A/Brisbane/59/2007, IVR-148 (H1N1); A/Uruguay/716/2007, NYMC X-175C (H3N2) (an A/Brisbane/10/2007-like virus); and B/Brisbane/60/2008 |
| Licensed |
Nov 2009 |
| Recommendations |
one intramuscular injection in persons 18 years of age and older |
| Ingredients |
Formaldehyde, Polysorbate 80, Kanamycin (antibiotic), Egg protein, Neomycin sulphate, Virus: Influenza, cetyltrimethylammonium bromide (CTAB). |
Product Descriptions
|
Package Insert (FDA)
Immune system disorders:
Hypersensitivity reactions (including throat and/or mouth edema, anaphylaxis, and anaphylactic shock) Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders:
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks. Guillain-Barré Syndrome
Nervous system disorders:
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks. Guillain-Barré Syndrome
Nervous system disorders:
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks. Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.
Carcinogenesis, Mutagenesis, Impairment of Fertility
AGRIFLU has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility. AGRIFLU has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility.
|
| Arepanrix
H1N1 AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine |
|
|
|
| Manufacturer |
GlaxoSmithKline |
| Microorganism |
A/California/7/2009 (H1N1)v-like strain (X-179A) 3.75µg HA |
| Licensed |
10/13/2009 (Canada) |
| Recommendations |
Adults aged 18-60 years: The need for a second dose is currently unknown (If a second dose is needed, it should be given after an interval of at least three weeks)
Children and adolescents aged 10-17 years: No clinical data are available for any influenza vaccines with AS03 in this age group. Consideration may be given to dosing in accordance with recommendations for adults.
Children aged 3-9 years: Based on limited clinical data available for AS03-adjuvanted H5N1 vaccine containing 3.75 ìg HA derived from A/Vietnam/1194/2004 in this age group, 0.25mL of vaccine (i.e. half of the adult dose) at an elected date and a second dose administered at least three weeks later may be considered sufficient. See section Pharmacodynamics.
Children aged from 6-35 months: No clinical data are available for influenza vaccines with AS03 in this age group. Consideration may be given to dosing in accordance with the recommendation in children aged 3-9 years.
Children aged less than 6 months: Vaccination is not currently recommended in this age group. |
| Ingredients |
Formaldehyde, Polysorbate 80, Squalene, Thimerosal, Mercury, Egg protein, Sodium deoxycholate, DL-á-tocopherol. |
Product Descriptions
|
Package insert
Manufacurer leaflet (GSK)
|
| Begrivac
Influenza vaccine (split virion, inactivated) |
|
|
|
| Manufacturer |
Wyeth |
| Microorganism |
Influenza virus |
| Licensed |
08/13/1998 |
| Recommendations |
From children 6 months and older, one i.m. injection, size of dose smaller for 6-36 months, booster dose recommended for children who have not previously been vaccinated |
| Ingredients |
Formaldehyde, Polymyxin B, Polysorbate 80, Sucrose, Sodium chloride, Potassium dihydrogen phosphate, Disodium phosphate dehydrate, Potassium chloride, Egg protein, Virus: Influenza virus antigens, Magnesium chloride hexahydrate, Diethylether. |
Product Descriptions
|
http://medguides.medicines.org.uk/displaypage.aspx?t=medicine&i=52
http://emc.medicines.org.uk/emc/industry/default.asp?remoteSearch=Begrivac
http://www.google.com/search?hl=en&safe=off&q=Begrivac%2C+intramuscular
http://www.pei.de/nn_163516/EN/drugs/impfstoffe-am-en/influenza-en/influenza-node-en.html?__nnn=true
|
| Celvapan (swine flu)
Pandemic influenza vaccine (H1N1) (whole virion, Vero cell derived, inactivated) |
|
|
|
| Manufacturer |
Baxter AG |
| Microorganism |
A/California/07/2009 (H1N1) 7.5 micrograms |
| Licensed |
04/03/2009 (EU/1/08/506/001) |
| Recommendations |
Adults and elderly - A dose (0.5 ml) of the vaccine will be given. A second dose of the vaccine should be given after an interval of at least three weeks.
Children and adolescents aged 6 months to 17 years of age -- If it is considered that you or your child needs to be vaccinated, you/he/she may receive one dose of 0.5 ml vaccine and a second dose of 0.5 ml at least three weeks later.
Children aged less than 6 months -- Vaccination is not currently recommended in this age group.
|
| Ingredients |
Formaldehyde, Polysorbate 80, Sucrose, Sodium chloride, Trometamol, Benzonase, propagated in Vero cells . |
Product Descriptions
|
Package Insert
|
| Enzira
Influenza vaccine (split virion, inactivated) |
|
|
|
| Manufacturer |
CSL |
| Microorganism |
Influenza |
| Licensed |
04/19/2005 |
| Recommendations |
Adults and children from 36 months, children from 6 to 36 months at a reduced dosage, second dose should be given for children that are previously unvaccinated |
| Ingredients |
Sodium chloride, Potassium dihydrogen phosphate, Potassium chloride, Sodium dihydrogen phosphate dehydrate, Egg protein, Calcium chloride, Virus: Influenza, Anhydrous disodium phosphate. |
Product Descriptions
|
http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=16589
|
| Fluad®
Influenza vaccine |
|
|
|
| Manufacturer |
Chiron |
| Microorganism |
Infleunza virus |
| Licensed |
(EU) |
| Recommendations |
|
| Ingredients |
Squalene, MF59. |
Product Descriptions
|
|
| Fluarix®
Influenza Virus Vaccine |
|
|
|
| Manufacturer |
GlaxoSmithKline |
| Microorganism |
The Influenza virus. |
| Licensed |
08/31/2005 |
| Recommendations |
Not for use in children. Single dose for adults |
| Ingredients |
Formaldehyde, Gentamicin Sulfate, Latex, Polysorbate 80, Thimerosal, Ovalbumin (egg), Egg protein, Influenza A virus hemagglutinin, Influenza B virus hemagglutinin, Octoxynol-10 (or 9), alpha-tocopheryl, Hydrogen succinate, Hydrocortisone, Sodium deoxycholate. |
Product Descriptions
|
Prescribing Information
Safety Data Sheet
http://www.fda.gov/cber/efoi/approve.htm
|
| FluLaval
Influenza Virus Vaccine |
|
|
|
| Manufacturer |
GlaxoSmithKline |
| Microorganism |
Influenza strains A/New Caledonia/20/99 (H1N1), 15 mcg; A/Wisconsin/67/2005 (H3N2), 15 mcg; B/Malaysia/2506/2004 |
| Licensed |
10/05/2006 |
| Recommendations |
Age 18 or older, single injection. |
| Ingredients |
Formaldehyde, Thimerosal, Mercury, Egg protein, Influenza A virus hemagglutinin, Influenza B virus hemagglutinin, Sodium deoxycholate. |
Product Descriptions
|
Prescribing Information
http://www.fda.gov/cber/efoi/approve.htm
|
| FluMist®
Live, intranasal influenzae |
|
|
|
| Manufacturer |
MedImmune, Wyeth |
| Microorganism |
H1N1, H3N2, B/Jilin/20/2003 (B/Shanghai/361/2002-13 like strains of Influenza virus |
| Licensed |
01/05/2007 |
| Recommendations |
Ages 2-49 |
| Ingredients |
Gentamicin Sulfate, Monosodium Glutamate (MSG), Sucrose, Potassium phosphate. |
Product Descriptions
|
Prescribing Info
http://www.fda.gov/cber/efoi/approve.htm
|
| Fluvax
Inactivated Influenza Vaccine (Split Virion) |
|
|
|
| Manufacturer |
CSL Limited |
| Microorganism |
Influenza |
| Licensed |
|
| Recommendations |
One injection yearly, from three months of age with differing strengths according to age. |
| Ingredients |
Neomycin, Polymyxin B, Sucrose, Sodium chloride, Sodium phosphate-monobasic, Potassium chloride, Egg protein, Virus: Influenza, Sodium phosphate- dibasic anhydrous, Potassium phosphate- monobasic, Sodium taurodeoxycholate. |
Product Descriptions
|
Package Insert
|
| Fluviral, Fluviral S/F
Influenza Virus Vaccine Trivalent, Inactivated Whole-Virion Active Immunizing Agent |
|
|
|
| Manufacturer |
Shire (Canada) |
| Microorganism |
Influenza virus |
| Licensed |
|
| Recommendations |
Annually in the fall. Children under 9 years of age require two injections one month apart, the first time they have the vaccine. Differing dosages for different age groups, from 6 months up. |
| Ingredients |
Formaldehyde, Thimerosal, Egg protein, Virus: Influenza, Sodium deoxycholate, Triton X-100. |
Product Descriptions
|
Package Insert
|
| Fluvirin®
Purified Surface Antigen Vaccine, Trivalent, Types A and B |
|
|
|
| Manufacturer |
Chiron Corporation |
| Microorganism |
Influenza virus H1N1, H3N2, B/Malaysia/2506/2004 strains |
| Licensed |
07/21/2006 |
| Recommendations |
Not for use for patients under four years of age: 1 or 2 injections for those 4 to 8 years of age, one injection for those 9 years of age or older. |
| Ingredients |
Neomycin, Polymyxin B, Thimerosal, Egg protein, Triton N101, M phosphate- buffered saline. |
Product Descriptions
|
Package Insert
http://www.fda.gov/cber/efoi/approve.htm
|
| Fluzone®
influenza virus vaccine trivalent, inactivated |
|
|
|
| Manufacturer |
Aventis Pasteur |
| Microorganism |
Influenza virus types A and B -- A/New Caledonia/20/99, A/Wyoming/03/2003 (an A/Fujian/411/2002-like, B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like) strains |
| Licensed |
07/10/2006 |
| Recommendations |
One or two i.m. injections for those 6 months of age or older, (reduced potency for age 6 to 35 months). |
| Ingredients |
Formaldehyde, Gelatin, Latex, Thimerosal, Egg protein, Virus: Influenza. |
Product Descriptions
|
University: http://www.vaccinesafety.edu/components-Influenza.htm
http://www.fluzone.com/
http://www.vaccineshoppe.com/us_pdf/fluzone_2005.2006_5097.5098.pdf
http://www.fda.gov/cber/label/inflave071405LB.pdf
http://www.fda.gov/cber/efoi/approve.htm
|
| Focetria (swine flu)
Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) |
|
|
|
| Manufacturer |
Novartis Vaccines and Diagnostics |
| Microorganism |
A/California/7/2009 (H1N1)v like strain (X-179A181) |
| Licensed |
02 May 2007 (EU/1/07/385/001, EU/1/07/385/002) |
| Recommendations |
Adults (18-60 years)and elderly -- One dose of 0.5 ml at an elected date. A second dose of vaccine should preferably be given. There should beafter an interval of at least three weeks between the first and second dose. However, the currently available immunogenicity data obtained at three weeks after administration of Focetria (H1N1) to a limited number of healthy adults aged 18-60 years suggest that a single dose may be sufficient in this age group.
Elderly (>60 years): One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks. See section 5.1.
Children and adolescents 6 months to 17 years of age -- One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks.
Children and adolescents aged 9-17 years: One dose of 0.5 ml at an elected date. A second dose of vaccine should preferably be given. There should be an interval of at least three weeks between the first and second dose.
Children and adolescents 6 months to 8 years of age: One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks.
Children aged less than 6 months: Vaccination is not currently recommended in this age group.
|
| Ingredients |
Polysorbate 80, Sorbitol, Squalene, Sodium chloride, Potassium dihydrogen phosphate, Potassium chloride, Sodium citrate, Egg protein, Calcium chloride, Magnesium chloride hexahydrate, MF59, Disodium phosphate dihydrate, Citric acid. |
Product Descriptions
|
Package Insert
|
| Grippol
Vaccination for flu prevention three-valence polymer-sub-single liquid |
|
|
|
| Manufacturer |
Institute of Immunology |
| Microorganism |
Influenza |
| Licensed |
|
| Recommendations |
children from 6 months, 3 doses with four week intervals ; over 3 years, one dose |
| Ingredients |
Virus: Influenza, Superficial glycoproteins (gemagglutinin and neyroamynidasa), Polyoxidonium, Hemagglutinin culture flu viruses of type A(H1N1), A(H3N2). |
Product Descriptions
|
Package Insert
|
| Inflexal, Inflexal S, Inflexal V
Influenza vaccine (surface antigen, inactivated, virosomic) |
|
|
|
| Manufacturer |
Sanofi Pasteur |
| Microorganism |
Influenza |
| Licensed |
03/29/2005 |
| Recommendations |
from six months, higher dosage for those over 3 years of age |
| Ingredients |
Sodium chloride, Egg protein, Virus: Influenza, Disodium dehydrogenate phosphate, Potassium dehydrogenate phosphate, Lecithin. |
Product Descriptions
|
http://www.crucell.com/Products-Inflexal_V
http://www.angelini.it/public/schedepharma/inflexal.htm
http://www.pei.de/nn_163516/EN/drugs/impfstoffe-am-en/influenza-en/influenza-node-en.html?__nnn=true
|
| Influenza A (H1N1) 2009 Monovalent Vaccine
Swine Flu, inactivated |
|
|
|
| Manufacturer |
Sanofi Pasteur |
| Microorganism |
Influenza A/California/07/2009 (H1N1) |
| Licensed |
|
| Recommendations |
Children:
-6 through 35 months of age (0.25 mL dose, intramuscular injection): Two 0.25 mL doses approximately one month apart. (2.2)
-36 months through 9 years of age (0.5 mL dose, intramuscular injection): Two 0.5 mL doses approximately one month apart. (2.2)
- 10 years of age and older: A single 0.5 mL dose, intramuscular injection.
Adults: A single 0.5 mL dose, intramuscular injection. |
| Ingredients |
Formaldehyde, Gelatin, Sucrose, Thimerosal, Sodium chloride, Sodium phosphate, Chick embryo cells, Triton X-100, Polyethylene glycol. |
Product Descriptions
|
(Thimerosol ) 25 mcg mercury is present in multi-does vaccine and not single doses.
Manufacturer Package Insert (FDA)
"Neither Fluzone vaccine nor Influenza A (H1N1) 2009 Monovalent Vaccine have been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility. "
"The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS)... Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported. Microscopic polyangitis (vasculitis) has been reported temporally associated with influenza vaccination. "
|
| Influenza A (H1N1) 2009 Monovalent Vaccine
Swine Flu inactivated |
|
|
|
| Manufacturer |
CSL Limited |
| Microorganism |
influenza A/California/7/2009 (H1N1)v-like virus. |
| Licensed |
Initial US approval 2007, US License No. 1764 |
| Recommendations |
Adults 18 years of age and older: A single 0.5 mL intramuscular injection. |
| Ingredients |
Beta-propiolactone, Polymyxin B, Sucrose, Thimerosal, Mercury, Sodium chloride, Sodium phosphate-monobasic, Ovalbumin (egg), Chick embryo cells, Neomycin sulphate, Calcium chloride, Sodium phosphate- dibasic anhydrous, Potassium phosphate- monobasic, Sodium taurodeoxycholate, Triton X-100. |
Product Descriptions
|
Package Insert (FDA)
Influenza A (H1N1) 2009 Monovalent Vaccine, a sterile suspension for intramuscular injection, is supplied in two presentations: 0.5 mL preservative-free, single-dose, pre-filled syringe.
• 5 mL multi-dose vial containing ten doses. Thimerosal, a mercury derivative, is added as a preservative; each 0.5 mL dose contains 24.5 micrograms (mcg) of mercury. 0.5 mL preservative-free, single-dose, pre-filled syringe.
"If GBS has occurred within 6 weeks of previous influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks. "
The following adverse reactions also include those identified during postapproval use of AFLURIA outside the US since 1985:
Blood and lymphatic system disorders- Transient thrombocytopenia
Allergic reactions including anaphylactic shock and serum sickness
Nervous system disorders - Neuralgia, paresthesia, and convulsions; encephalopathy, neuritis or neuropathy, transverse myelitis, and GBS
Vascular disorders: Vasculitis with transient renal involvement
|
| Influenza A (H1N1) 2009 Monovalent Vaccine
Swine Flu, inactivated |
|
|
|
| Manufacturer |
Novartis Vaccines and Diagnostics Ltd. |
| Microorganism |
A/California/7/2009 (H1N1)v-like virus |
| Licensed |
|
| Recommendations |
Children 4 through 9 years of age: Two 0.5-mL intramuscular injections approximately 1 month apart
Children 10 through 17 years of age: A single 0.5-mL intramuscular injection
Adults 18 years of age and older: A single 0.5-mL intramuscular injection |
| Ingredients |
Beta-propiolactone, Neomycin, Polymyxin B, Thimerosal, Mercury, Chick embryo cells, Egg protein, Nonylphenol ethoxylate. |
Product Descriptions
|
Package Insert (FDA)
Guillain-Barr¨¦ Syndrome
If Guillain-Barr¨¦ syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks.
Immune system disorders: Hypersensitivity reactions (including throat and/or mouth edema). In rare cases, hypersensitivity reactions have lead to anaphylactic shock and death.
Cardiovascular disorders: Vasculitis
Serious allergic reactions, including anaphylactic shock, have been observed in individuals...
Prefilled single dose syringe, 0.5-mL. Thimerosal, a mercury derivative used during manufacture, is removed by subsequent purification steps to a trace amount (1 mcg mercury per 0.5-mL dose)
Multidose vial, 5-mL. Contains thimerosal, a mercury derivative (25 mcg mercury per 0.5-mL dose). Thimerosal is added as preservative.
Serious allergic reactions, including anaphylactic shock, have been observed in individuals...
Prefilled single dose syringe, 0.5-mL. Thimerosal, a mercury derivative used during manufacture, is removed by subsequent purification steps to a trace amount (1 mcg mercury per 0.5-mL dose)
Multidose vial, 5-mL. Contains thimerosal, a mercury derivative (25 mcg mercury per 0.5-mL dose). Thimerosal is added as preservative.
Serious allergic reactions, including anaphylactic shock, have been observed in individuals...
Prefilled single dose syringe, 0.5-mL. Thimerosal, a mercury derivative used during manufacture, is removed by subsequent purification steps to a trace amount (1 mcg mercury per 0.5-mL dose)
Multidose vial, 5-mL. Contains thimerosal, a mercury derivative (25 mcg mercury per 0.5-mL dose). Thimerosal is added as preservative.
|
| Influenza A (H1N1) 2009 Monovalent Vaccine
Swine Flu live, intranasal, attenuated |
|
|
|
| Manufacturer |
MedImmune, LLC |
| Microorganism |
Six internal gene segments responsible for ca, ts, and att phenotypes are derived from a master donor virus (MDV) and pandemic (H1N1) 2009 wild-type virus |
| Licensed |
|
| Recommendations |
Children (2-9 years) - 2 doses (0.2 mL each, approximately 1 month apart)
Children, adolescents and adults (10-49 years) - 1 dose (0.2 mL) |
| Ingredients |
Gentamicin Sulfate, Gelatin, Monosodium Glutamate (MSG), Sucrose, Potassium phosphate, Chick embryo cells, Potassium phosphate- monobasic, Arginine. |
Product Descriptions
|
Package Insert (FDA)
Contraindications: Hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or life threatening reactions to previous influenza vaccination.
Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or FluMist should be based on careful consideration of the potential benefits and potential risks. If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or FluMist should be based on careful consideration of the potential benefits and potential risks If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or FluMist should be based on careful consideration of the potential benefits and potential risks
|
| Influenza A (H1N1) 2009 Monovalent Vaccine
split-virion, inactivated influenza virus subtype A |
|
|
|
| Manufacturer |
ID Biomedical Corporation of Quebec (IDB) (Distributed by GlaxoSmithKline) |
| Microorganism |
A/California/7/2009 (H1N1)v-like virus. |
| Licensed |
Nov 10, 2009 |
| Recommendations |
Adults 18 years of age and older: A single 0.5-mL intramuscular injection |
| Ingredients |
Formaldehyde, Thimerosal, Mercury, Ovalbumin (egg), Egg protein, Virus: Influenza virus antigens, Sodium deoxycholate. |
Product Descriptions
|
Package Insert (FDA)
*If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks. Limitations of Vaccine Effectiveness: Vaccination with Influenza A (H1N1) 2009 Monovalent Vaccine may not protect all susceptible individuals.
Nervous System Disorders: Dizziness, paresthesia, hypoesthesia, hypokinesia, tremor, somnolence, syncope, Guillain-Barré syndrome, convulsions/seizures, facial or cranial nerve paralysis, encephalopathy, limb paralysis.
embryonated hens’ eggs.
formaldehyde
|
| Influvac
Influenza vaccine, surface antigen, inactivated |
|
|
|
| Manufacturer |
Solvay-Pharma |
| Microorganism |
Influenza |
| Licensed |
07/15/2005 |
| Recommendations |
Adults, elderly, and children over 36 months, single injection. |
| Ingredients |
Formaldehyde, Sodium chloride, Potassium dihydrogen phosphate, Disodium phosphate dehydrate, Potassium chloride, Egg protein, Calcium chloride, Magnesium chloride hexahydrate, Virus: Influenza. |
Product Descriptions
|
Package Insert
|
| Mastaflu
influenza vaccine, surface antigen, inactivated |
|
|
|
| Manufacturer |
Solvay |
| Microorganism |
Influenza |
| Licensed |
|
| Recommendations |
adults and children from 36 months, single dose |
| Ingredients |
Sodium chloride, Potassium dihydrogen phosphate, Disodium phosphate dehydrate, Potassium chloride, Egg protein, Calcium chloride, Magnesium chloride hexahydrate, Virus: Influenza. |
Product Descriptions
|
http://emc.medicines.org.uk/eMC/assets/c/html/DisplayDoc.asp?DocumentID=12737
|
| Mutagrip
Influenza Vaccine (SPLIT VIRION) |
|
|
|
| Manufacturer |
Aventis |
| Microorganism |
Influenza |
| Licensed |
08/28/1998 |
| Recommendations |
Single 0.5 mL i.m. injection for those 36 months of age and older. |
| Ingredients |
Sodium chloride, Disodium phosphate dehydrate, Potassium chloride, Monopotassium phosphate, Egg protein, Virus: Influenza. |
Product Descriptions
|
http://home.intekom.com/pharm/ranbaxy/mutagrip.html
German: http://www.impfkritik.de/fachinfo/influenza-mutagrip-aventis-2004-2005.pdf
http://www.pei.de/nn_163516/EN/drugs/impfstoffe-am-en/influenza-en/influenza-node-en.html?__nnn=true
|
| Optaflu
|
|
|
|
| Manufacturer |
Novartis |
| Microorganism |
Influenza (flu) virus |
| Licensed |
June 13, 2007 (EU) |
| Recommendations |
One intramuscular injection, seasonally |
| Ingredients |
Dog kidney cells. |
Product Descriptions
|
Dr. Sherri Tenpenny Speaks Out
"The Hidden Hazards of the New Flu Vaccine, OptaFlu"
|
| Pandemrix (swine flu)
Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) |
|
|
|
| Manufacturer |
GlaxoSmithKline |
| Microorganism |
A/California/7/2009 (H1N1)v-like strain (X-179A) |
| Licensed |
20/05/2008 (EU/1/08/452/001) |
| Recommendations |
Adults aged 18-60 years: One dose of 0.5 ml at an elected date. A second dose of vaccine should preferably be given. There should be an interval of at least threeweeks between the first and second dose. However, preliminary immunogenicity data obtained at three weeks after administration of an investigational formulation of Pandemrix (H1N1) to a limited number of healthy adults aged 18-60 years suggest that a single dose may be sufficient in this age group. See section 5.1.
Elderly (>60 years) --One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks. See section 5.1.
Children and adolescents aged 10-17 years -- If vaccination is considered to be necessary, consideration may be given to dosing in accordance with the recommendations for adults. However, the choice of dose for this age group should take into
account the available data on safety and immunogenicity in adults and in children aged from 3-9 years.
Children aged 3-9 years -- If vaccination is considered to be necessary, the available data suggest that administration of 0.25 ml
of vaccine (i.e. half of the adult dose) at an elected date and a second dose administered at least three weeks later may be sufficient. There are very limited safety and immunogenicity data available on the administration of AS03-
adjuvanted vaccine containing 3.75 ìg HA derived from A/Vietnam/1194/2004 (H5N1) and on administration of half a dose of the same vaccine (i.e. 1.875 ìg HA and half the amount of AS03 adjuvant in 0.25 ml ) at 0 and 21 days in this age group.
Children aged from 6 months to 3 years -- If vaccination is considered to be necessary, consideration may be given to dosing in accordance with the recommendation in children aged 3-9 years.
Children aged less than 6 months -- Vaccination is not currently recommended in this age group. |
| Ingredients |
Formaldehyde, Gentamicin Sulfate, Polysorbate 80, Squalene, Thimerosal, Mercury, Sodium chloride, Ovalbumin (egg), Potassium dihydrogen phosphate, Potassium chloride, Egg protein, Magnesium chloride hexahydrate, Octoxynol-10 (or 9), Sodium deoxycholate, AS03 , DL-á-tocopherol, Disodium hydrogen phosphate . |
Product Descriptions
|
Package Insert (GSK manufacturer)
|
| Vaxigrip
Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) |
|
|
|
| Manufacturer |
Sanofi Pasteur |
| Microorganism |
Influenza |
| Licensed |
|
| Recommendations |
6 months of age or older |
| Ingredients |
Formaldehyde, Neomycin, Sucrose, Thimerosal, Sodium phosphate, Virus: Influenza, Triton X-100. |
Product Descriptions
|
Package Insert
|
|
WAVE - Common Menu
|
